Allele-specific copy number analysis (ASCNA) is critical to define the extent of tumor suppressor loss of function (LOF) and contextualize the clinical response to synthetic lethal (SL) agents. Targeting tumor suppressors through SL is poised to usher in a new wave of precision oncology, but there remains a need for assays that provide reliable ASCNA. Learn how Repare Therapeutics developed an Archer technology-based NGS assay designed to perform retrospective ASCNA and identify biallelic LOF in genes predicted to sensitize to an investigational SL agent. Hear how their post-hoc analysis demonstrated the potential of biallelic LOF as a relevant biomarker in patients with solid tumors treated with an SL agent.
For research use only. Not for use in diagnostic procedures.
